Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myasthenia Gravis, Generalized: early-phase trial registry
1 of 4 indexed Myasthenia Gravis, Generalized trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Myasthenia Gravis, Generalized: 4 US clinical trials tracked, 1 recruiting.
Myasthenia Gravis, Generalized is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Cartesian Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition myasthenia-gravis-generalized
OPEN 1 | RECR 25% | LATE 1 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Myasthenia Gravis, Generalized lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myasthenia Gravis, Generalized on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myasthenia Gravis, Generalized is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Myasthenia Gravis Foundation of America Global MG Patient Registry
Myasthenia Gravis Foundation of America
NCT06617741
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
argenx
NCT06298552
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Dianthus Therapeutics
NCT06282159
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
Cartesian Therapeutics
NCT04146051
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Myasthenia Gravis, Generalized records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myasthenia Gravis, Generalized trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myasthenia Gravis, Generalized page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Myasthenia Gravis, Generalized trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cartesian Therapeutics sponsors the most Myasthenia Gravis, Generalized trials on record, review their full trial history before evaluating a specific study. See Cartesian Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myasthenia Gravis, Generalized condition card totals 4 registered trials; most-linked intervention Placebo IV; top US site state Kansas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.